Crestor and Cannabis Interaction Profile: What You Need to Know

How Rosuvastatin Is Metabolized

Rosuvastatin does not follow the classic CYP3A4-heavy statin pathway that governs atorvastatin or simvastatin. About 10% of an oral dose undergoes hepatic metabolism via CYP2C9, producing the N-desmethyl metabolite, while the majority is excreted unchanged in feces. Uptake into hepatocytes depends heavily on organic anion transporting polypeptide 1B1 (OATP1B1) and efflux is regulated by breast cancer resistance protein (BCRP, encoded by the ABCG2 gene). [1]

Why the Transport Pathway Matters More Than CYP Here

Because rosuvastatin relies on transporter proteins rather than CYP enzymes for most of its pharmacokinetics, inhibitors of OATP1B1 and BCRP are more dangerous than a standard CYP3A4 inhibitor would be. The FDA prescribing information lists cyclosporine as capable of raising rosuvastatin AUC by roughly 7-fold via these transporters. [2] Any substance that inhibits BCRP or OATP1B1 therefore has the potential to meaningfully increase rosuvastatin systemic exposure, driving both efficacy and toxicity upward.

CYP2C9 Contribution

The CYP2C9 fraction of rosuvastatin metabolism is modest but not negligible. Individuals who are CYP2C9 poor metabolizers (roughly 3-5% of European populations) already carry higher rosuvastatin plasma concentrations at standard doses. Adding a CYP2C9 inhibitor in this subgroup compounds exposure further. [1]

What Cannabis Does to Drug-Metabolizing Enzymes

Cannabis contains hundreds of phytochemicals. For drug interactions, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most relevant.

CBD's Effect on CYP Enzymes and Transporters

CBD is a potent inhibitor of CYP2C9 in vitro and in vivo. A 2020 pharmacokinetic study published in the British Journal of Clinical Pharmacology demonstrated that pharmaceutical-grade CBD (Epidiolex, 750 mg twice daily) increased warfarin AUC by approximately 30% through CYP2C9 inhibition in healthy volunteers. [3] Warfarin is a narrow-therapeutic-index CYP2C9 substrate. Rosuvastatin shares the CYP2C9 pathway partially, so a quantitatively smaller but directionally similar effect on rosuvastatin exposure is biologically plausible.

CBD has also been shown in cell models to inhibit BCRP efflux transport. A 2021 study in the journal Pharmaceutics found that CBD inhibited BCRP-mediated transport with an IC50 in the low-micromolar range, concentrations that may be reached at high recreational or therapeutic CBD doses. [4] Because BCRP is a primary efflux transporter for rosuvastatin in the intestinal wall and liver, BCRP inhibition could raise peak rosuvastatin concentrations.

THC's Metabolic Footprint

THC is metabolized by CYP2C9 and CYP3A4. As a substrate competing for CYP2C9, THC could theoretically reduce CYP2C9 availability for rosuvastatin's partial metabolism, though the clinical magnitude of this competitive inhibition at typical THC doses is unquantified. THC also weakly induces CYP1A2, which has no direct bearing on rosuvastatin clearance. A 2022 review in Clinical Pharmacokinetics catalogued 13 documented THC-drug interactions mediated through CYP2C9 and CYP3A4, underscoring that this is not a theoretical concern. [5]

Frequency of Use Changes the Picture

Occasional cannabis use (once weekly or less) produces lower and more transient plasma CBD and THC concentrations than daily or multiple-times-daily use. Heavy daily use is associated with greater enzyme inhibition. A patient using a high-CBD product daily alongside rosuvastatin 20-40 mg sits in a meaningfully different risk category than someone who uses low-potency cannabis recreationally once a month.

The Pharmacodynamic Interaction: Heart Rate and Cardiovascular Risk

Statins like rosuvastatin are prescribed largely to reduce cardiovascular event risk. Cannabis complicates that goal through direct cardiac effects.

Acute Tachycardia and Hemodynamic Changes

Acute THC exposure reliably increases heart rate. A systematic review in the Journal of the American Heart Association (2018) documented that acute cannabis use raises heart rate by 20-100% above baseline, with the effect peaking within 15 minutes of inhalation and lasting 2-3 hours. [6] In patients with established coronary artery disease or those at high Framingham risk score, statin therapy is specifically intended to stabilize vulnerable plaques and reduce myocardial oxygen demand. Superimposed tachycardia from THC increases myocardial oxygen consumption and can precipitate angina or, in susceptible individuals, arrhythmia.

Reported Cardiovascular Events in Cannabis Users

The American Heart Association's 2020 scientific statement on cannabis and cardiovascular health, signed by Metzl et al., stated: "Marijuana use is associated with dose-related impairment in several cardiovascular functions and may be associated with increased risk of myocardial infarction in younger patients." [7] This is not a hypothetical risk. Cannabis-associated vasospasm, Kounis syndrome (hypersensitivity coronary artery spasm), and stress-cardiomyopathy have been reported in otherwise healthy young adults.

Patients taking rosuvastatin because they have documented atherosclerosis are precisely the population for whom this additional hemodynamic load is least tolerable.

Blood Pressure Effects: Mixed and Context-Dependent

Acute cannabis use produces an initial blood pressure rise followed by hypotension with postural changes. Chronic heavy use may be associated with elevated baseline blood pressure, though the evidence here is weaker than for acute effects. For a patient on rosuvastatin who also takes antihypertensives, cannabis-induced postural hypotension represents an additional fall and syncope risk, particularly in older adults.

Myopathy Risk: Do Cannabis and Rosuvastatin Both Affect Muscle?

Statin-Associated Muscle Symptoms

Statin-associated muscle symptoms (SAMS) occur in roughly 5-10% of patients on statins in clinical practice, though the SAMSON trial (N=60 statin-tolerant, N=60 statin-intolerant patients) used a rigorous blinded N-of-1 design and found that 90% of symptoms on statin were also present on placebo, suggesting nocebo contribution is substantial. [8] Regardless of mechanism, clinical myopathy with CK elevation greater than 10 times the upper limit of normal requires statin discontinuation.

Cannabis and Muscle Toxicity

Case reports and a 2021 clinical toxicology paper in Clinical Toxicology described a syndrome termed cannabinoid hyperemesis syndrome adjacent myopathy, where heavy cannabis users presented with rhabdomyolysis in the absence of other precipitants. [9] The proposed mechanisms include mitochondrial toxicity from high-dose cannabinoids and electrolyte derangements secondary to protracted vomiting. When rhabdomyolysis occurs in a patient also on a statin, the clinical picture is confounded and CK levels may be severely elevated.

Practical Implication for CK Monitoring

Any patient on rosuvastatin who reports unexplained muscle pain, weakness, or dark urine and also uses cannabis should have an urgent CK level drawn. The presence of cannabis use should be disclosed to the clinician interpreting results, as it changes the differential diagnosis.

Rosuvastatin and Alcohol: A Related Concern

Many patients who ask about cannabis also ask whether alcohol use is safe on Crestor.

Hepatotoxicity Risk

Both alcohol and rosuvastatin can stress hepatic function. Rosuvastatin causes clinically significant liver enzyme elevation in fewer than 1% of patients at approved doses, per the FDA prescribing information. [2] Alcohol is hepatotoxic in a dose-dependent manner. The combination of heavy alcohol use (more than 14 standard drinks per week in men or more than 7 in women, per NIAAA definitions) [10] and statin therapy raises the risk of transaminase elevation beyond what either agent produces alone.

Rhabdomyolysis and Alcohol

Acute alcohol intoxication is itself a cause of rhabdomyolysis, particularly after binge episodes involving physical exertion or falls. Combining alcohol with a statin does not directly raise rhabdomyolysis risk through a pharmacokinetic mechanism for rosuvastatin specifically, but the pharmacodynamic picture of a patient with statin-induced mild myopathy who then binges is one that could push CK into the danger zone.

Clinical Guidance on Alcohol While Taking Crestor

The ACC/AHA 2019 guideline on primary prevention of cardiovascular disease does not set a specific alcohol limit for statin users. [11] The practical recommendation from HealthRX clinicians is to stay within low-risk drinking guidelines (no more than 1-2 standard drinks per day with alcohol-free days weekly) and to have LFTs checked annually or sooner if symptoms of liver dysfunction appear.

Practical Decision Framework: Cannabis Use Categories and Rosuvastatin Risk

The table below stratifies cannabis use patterns by estimated pharmacokinetic and pharmacodynamic risk in a patient taking rosuvastatin.

| Cannabis Use Pattern | Estimated PK Risk | Estimated PD Risk | Suggested Action | |---|---|---|---| | Rare recreational (less than monthly, low THC, smoked) | Low | Low-moderate (acute HR effect) | Disclose to prescriber; no dose change needed | | Weekly recreational, mixed THC/CBD | Moderate | Moderate | Disclose; monitor CK and LFTs at next scheduled visit | | Daily use, high-CBD product (oral/sublingual) | Moderate-high | Moderate | Disclose; consider CK and LFT check at 4-8 weeks; prescriber may adjust rosuvastatin dose | | Daily high-dose CBD (greater than 300 mg/day) | High | Moderate | Active management required; pharmacist or clinical pharmacology consult appropriate | | Daily high-THC concentrate (dabbing, vaping) | Moderate (PK) | High (cardiac) | Cardiovascular risk counseling; rosuvastatin dose review |

This framework has not been validated in a prospective trial. It is intended to guide clinical conversation, not replace individualized prescriber judgment.

What the FDA Label Says (and Does Not Say)

The current FDA prescribing information for rosuvastatin (Crestor and generics) lists the following interactants by mechanism: [2]

• Cyclosporine: 7-fold AUC increase via OATP1B1/BCRP inhibition. Concomitant use is contraindicated.
• Certain antivirals (lopinavir/ritonavir, atazanavir/ritonavir): 2-3 fold AUC increase. Dose cap of 10 mg/day applies.
• Gemfibrozil: approximately 2-fold AUC increase. Dose cap of 10 mg/day.
• Antacids (aluminum/magnesium hydroxide): 54% AUC reduction. Separate administration by 2 hours.

Cannabis appears nowhere in the label. This reflects the state of formal regulatory science, not the state of pharmacological understanding. The mechanisms by which CBD inhibits BCRP and CYP2C9 are the same mechanisms that cause the cyclosporine and antiviral interactions that the FDA does flag. The label's silence on cannabis should not be read as a declaration that co-use is safe.

What to Tell Your Prescriber

Disclosure is the single most important step a patient can take. A 2021 survey published in JAMA Network Open (N=2,774 adults) found that only 25% of cannabis users reported disclosing use to their physician. [12] Non-disclosure prevents prescribers from adjusting statin doses, ordering appropriate labs, or counseling on cardiovascular risk.

When disclosing, be specific about:

1. Frequency of use (daily, weekly, occasional)
2. Product type (flower, oil, concentrate, edible)
3. CBD-to-THC ratio if known
4. Route of administration (inhaled, oral, sublingual)
5. Approximate dose in milligrams if using a labeled product

Prescribers who have this information can make an informed decision about whether rosuvastatin dose adjustment, more frequent CK and LFT monitoring, or a change in statin selection is warranted.

Choosing a Statin for Cannabis Users: Is Rosuvastatin the Right Choice?

Rosuvastatin is actually a relatively favorable statin choice for cannabis users compared to simvastatin or lovastatin, both of which depend heavily on CYP3A4. CBD and THC are weak-to-moderate CYP3A4 inhibitors, meaning simvastatin and lovastatin carry a higher plasma-level escalation risk in cannabis users than rosuvastatin does.

Pravastatin is another option. It has no significant CYP metabolism and relies primarily on renal excretion and organic anion transporters. Pravastatin's OATP1B1 dependence is similar to rosuvastatin's, so the transporter-mediated risk with CBD is not entirely avoided, but the CYP2C9 component is absent.

Fluvastatin is the only statin that is a dedicated CYP2C9 substrate, making it potentially more sensitive to CBD inhibition than rosuvastatin.

The prescriber weighs cardiovascular benefit, lipid-lowering potency, and tolerability alongside interaction risk. Rosuvastatin's high potency and favorable safety profile at standard doses give it a justified place even in cannabis users, provided monitoring protocols are in place.

Monitoring Protocol Recommendations

For patients taking rosuvastatin who disclose cannabis use, a reasonable clinical monitoring approach includes:

• Baseline CK and comprehensive metabolic panel (CMP) before initiating or continuing rosuvastatin
• Repeat CK and LFTs at 6-12 weeks if cannabis use is daily or involves high-CBD products
• Annual LFTs and CK if use is stable, infrequent, and the patient is asymptomatic
• Urgent CK measurement for any new myalgia, muscle weakness, or brown urine
• 12-lead ECG if palpitations, chest pain, or unexplained dyspnea occurs in the context of acute cannabis use

Patients on rosuvastatin 40 mg (the maximum approved dose in the United States) [2] have a higher baseline myotoxicity risk than those on 5-10 mg and should be monitored more closely regardless of cannabis use.